The Animal Tumor Models Shared Resource provides services in three major areas including transgenic and knockout mice, preclinical oncology and animal histopathology services. The transgenic and knockout mouse production services were established in 1996 at the School of Medicine with the overall objective of providing genetically modified mouse models and supporting technologies to Stanford investigators at cost-effective rates. The Veterinary Service Center (VSC) in the Department of Comparative Medicine runs the animal histopathology service component of the Shared Resource. Major services include tumor analysis by histology, immunohistochemistry, and pathological interpretation. The preclinical oncology services are new additions to the Animal Tumor Models Shared Resource. These services were funded and established by the Cancer Center to support the development and testing of new compounds and to better meet the growing needs of the Cancer Center members for preclinical animal models and therapeutics. The objectives of the Shared Resource are: ? Consultation in all aspects of animal tumor models, including creation and analysis of tumor models and providing a database of tumor models in use by Stanford investigators ? Production of transgenic and knockout mice by embryo and embryonic stem cell manipulation and microinjection ? Full histopathology services for tissue processing, staining and pathological interpretation ? Preclinical oncology services for tumor induction, drug administration, toxicity studies, data collection and analysis Substantial cost savings, efficiencies and scientific advances accrue from providing these services through a centralized facility. The Shared Resource has generated over 500 transgenic and knockout mouse models in the last 5 years, each with multiple independent lines. Over 24,000 histology slides or tissue blocks were processed and over 670 pathology procedures were performed in 2008. The Shared Resource's services were acknowledged or co-authored in hundreds of publications in peer-reviewed journals. In calendar year 2008, Cancer Center members representing nine out of ten Programs utilized the Shared Resource. Future plans for the Shared Resource include implementation of tetraploid complementation to speed up knockout mouse production, expansion of the capacity of histopathology services, and offer services on complex tumor models such as orthotopic brain, prostate, pancreatic or renal tumor models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-08
Application #
8685166
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
8
Fiscal Year
2014
Total Cost
$164,789
Indirect Cost
$38,624
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15

Showing the most recent 10 out of 322 publications